Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase iv study in china

HIGHLIGHTS

• who: Xinghuai Sun from the Tafluprost, Primary open-angle glaucoma, Ocular hypertension, Clinical trial, Phase IV, China Shanghai Medical College, Fudan University, Shanghai, China have published the paper: Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China, in the Journal: (JOURNAL) of December/27,/2017
• what: Tafluprost shows stable effectiveness in lowering IOP with a manageable safety profile among Chinese patients with POAG and OH who were treatment-nau00efve or untreated within a month regardless of baseline IOP level or with unreached target . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.